Shots:
- J&J has reported additional findings from P-III (Vivacity-MG3) trial & ongoing OLE assessing nipocalimab + SoC (30mg/kg, IV loading dose followed by 15mg/kg, Q2W) vs PBO in anti-AChR+, anti-MuSK+ & anti-LRP4+ adults (n=153) with gMG
- Trial showed a -4.9 QMG score improvement over 22 & 24wks. & pts were 4x more likely to sustain improvement at 20wks.; 36.4% vs 10.5% maintained >75% of the study with improved QMG scores
- After 60wks. in OLE, nipocalimab showed a mean MG-ADL change of -5.64 for treatment arm & -6.01 for those switching from PBO, with 45% Antibody+ pts reduced or stopped steroids, with prednisone dosage decreasing from 23 to 10mg/day; data was presented at AAN 2025
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Receives the EC’s Approval for SC Rybrevant to Treat Advanced EGFR-Mutated NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
